Ross D Hannan Selected Research

RNA Polymerase I (Polymerase I, RNA)

1/2022	The therapeutic potential of RNA Polymerase I transcription inhibitor, CX-5461, in uterine leiomyosarcoma.
11/2021	CX-5461 Sensitizes DNA Damage Repair-proficient Castrate-resistant Prostate Cancer to PARP Inhibition.
1/2021	The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer.
11/2020	Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis.
1/2020	rDNA Chromatin Activity Status as a Biomarker of Sensitivity to the RNA Polymerase I Transcription Inhibitor CX-5461.
1/2020	Targeting the RNA Polymerase I Transcription for Cancer Therapy Comes of Age.
1/2019	First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study.
1/2017	Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population.
1/2017	Selective inhibition of RNA polymerase I transcription as a potential approach to treat African trypanosomiasis.
11/2016	The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ross D Hannan Research Topics

Disease

46	Neoplasms (Cancer) 01/2022 - 09/2008
7	Hypertrophy 05/2011 - 02/2002
6	Carcinogenesis 12/2020 - 01/2013
6	Lymphoma (Lymphomas) 01/2019 - 07/2012
5	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 12/2006
5	Hematologic Neoplasms (Hematological Malignancy) 11/2020 - 07/2012
5	Cardiomegaly (Heart Hypertrophy) 05/2011 - 02/2002
4	Prostatic Neoplasms (Prostate Cancer) 11/2021 - 11/2016
4	Leukemia 12/2020 - 07/2012
3	Genomic Instability 01/2021 - 01/2014
3	Heart Failure 01/2006 - 08/2003
2	Neuroblastoma 01/2020 - 11/2019
2	Melanoma (Melanoma, Malignant) 01/2018 - 10/2016
2	B-Cell Lymphoma (Lymphoma, B Cell) 11/2013 - 04/2013
1	Leiomyosarcoma 01/2022
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 11/2021
1	DNA Repair-Deficiency Disorders (Chromosome Instability Syndromes) 01/2020
1	ATR-X syndrome 01/2018
1	Starvation 05/2017
1	Breast Neoplasms (Breast Cancer) 01/2017
1	Huntington Disease (Huntington's Disease) 01/2017
1	African Trypanosomiasis (Nagana) 01/2017
1	Bone Marrow Failure Disorders 11/2015
1	Cockayne Syndrome (Syndrome, Cockayne) 06/2015
1	Xeroderma Pigmentosum (Kaposi's Disease) 06/2015
1	Trichothiodystrophy Syndromes 06/2015
1	Colorectal Neoplasms (Colorectal Cancer) 01/2014
1	Disease Progression 11/2013
1	Pathologic Constriction (Stenosis) 07/2013
1	Atherosclerotic Plaque (Atheroma) 07/2013

Drug/Important Bio-Agent (IBA)

16	RNA Polymerase I (Polymerase I, RNA)IBA 01/2022 - 02/2011
15	CX 5461IBA 01/2022 - 02/2011
13	Ribosomal DNA (rDNA)IBA 01/2021 - 06/2006
11	Proteins (Proteins, Gene)FDA Link 01/2020 - 08/2003
8	Mechanistic Target of Rapamycin Complex 1IBA 01/2020 - 09/2008
6	Ribosomal RNAIBA 01/2020 - 02/2011
5	Phosphotransferases (Kinase)IBA 11/2016 - 02/2002
4	Transcription Factors (Transcription Factor)IBA 01/2020 - 01/2014
3	ChromatinIBA 01/2020 - 01/2019
3	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2018 - 02/2002
3	ErbB Receptors (EGF Receptor)IBA 05/2011 - 02/2002
3	Angiotensin IIIBA 05/2011 - 02/2002
3	Atrial Natriuretic Factor (ANF)IBA 06/2006 - 02/2002
3	Epidermal Growth Factor (EGF)IBA 01/2006 - 02/2002
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 11/2021 - 01/2020
2	Androgen Receptors (Androgen Receptor)IBA 11/2021 - 11/2018
2	DNA (Deoxyribonucleic Acid)IBA 11/2020 - 10/2016
2	RNA (Ribonucleic Acid)IBA 11/2019 - 11/2016
2	Histones (Histone)IBA 01/2018 - 02/2015
2	HeterochromatinIBA 01/2018 - 01/2014
2	Everolimus FDA Link 01/2016 - 01/2013
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 12/2013 - 12/2006
2	DNA-Directed RNA Polymerases (RNA Polymerase)IBA 05/2013 - 02/2011
2	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2013 - 09/2004
2	LigandsIBA 05/2011 - 01/2006
2	Metalloproteases (Metalloproteinases)IBA 05/2011 - 01/2006
2	Hormones (Hormone)IBA 06/2006 - 05/2004
2	RTKI cpdIBA 01/2006 - 02/2002
2	urotensin IIIBA 09/2004 - 08/2003
2	2- (2- amino- 3- methoxyphenyl)- 4H- 1- benzopyran- 4- oneIBA 09/2004 - 02/2002
2	Mitogen-Activated Protein KinasesIBA 09/2004 - 02/2002
1	talazoparibIBA 11/2021
1	NAD (NADH)IBA 01/2021
1	CateninsIBA 12/2020
1	CohesinsIBA 12/2020
1	Progesterone Receptors (Progesterone Receptor)IBA 04/2020
1	Biomarkers (Surrogate Marker)IBA 01/2020
1	Ribosomal Proteins (Ribosomal Protein)IBA 11/2019
1	Carrier Proteins (Binding Protein)IBA 11/2019
1	Oncogene Proteins (Oncogene Protein)IBA 11/2019
1	N-Myc Proto-Oncogene ProteinIBA 11/2019
1	Long Noncoding RNAIBA 11/2019
1	Antineoplastic Agents (Antineoplastics)IBA 01/2019
1	enzalutamideIBA 11/2018
1	abirateroneIBA 11/2018
1	palbociclibIBA 01/2018
1	polyglutamineIBA 01/2017
1	BMH-21IBA 01/2017
1	proto-oncogene proteins pimIBA 11/2016
1	CX-6258IBA 11/2016
1	Sp1 Transcription FactorIBA 10/2016
1	Amino Acids FDA Link 08/2016
1	Eukaryotic Initiation Factor-4EIBA 01/2016
1	DiamondIBA 11/2015
1	NucleotidesIBA 06/2015
1	Tumor Suppressor Protein p53IBA 03/2014
1	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 01/2014
1	Calcibiotic Root Canal SealerIBA 01/2014
1	TOR Serine-Threonine KinasesIBA 12/2013
1	2- amino- 8- (4- (2- hydroxyethoxy)cyclohexyl)- 6- (6- methoxypyridin- 3- yl)- 4- methylpyrido(2,3- d)pyrimidin- 7(8H)- oneIBA 12/2013
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 12/2013
1	PlatinumIBA 12/2013
1	Paclitaxel (Taxol)FDA LinkGeneric 12/2013
1	mirdametinibIBA 12/2013
1	MK 2206IBA 11/2013
1	Indicators and Reagents (Reagents)IBA 08/2013

Therapy/Procedure

18	Therapeutics 11/2021 - 01/2006
2	Castration 11/2018 - 11/2016
1	Drug Therapy (Chemotherapy) 01/2017
1	Oral Administration 11/2016